BioSpace News Archive

MYND Life Sciences Inc. a life sciences company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce its CEO is presenting at Canaccord Genuity Group Inc.'s upcoming conference; New Paradigms and Treatment Approaches in Mental Health.

January 2021 marks the one-year anniversary of HSS Florida, a state-of-the-art facility in West Palm Beach that is part of Hospital for Special Surgery, the world’s leading academic medical center specializing in orthopedics, rheumatology and related disciplines.

Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, announced that CEO J. Robert Coleman, Ph.D., M.B.A., will present an update on COVI-VAC during the New York Academy of Science’s (NYAS) two-day webinar event, “Quest for a COVID-19 Vaccine,

New Orders, Production & Employment Growing; Supplier Deliveries Slowing at Faster Rate; Backlog Growing; Raw Materials Inventories Growing; Customers’ Inventories Too Low; Prices Increasing; Exports and Imports Growing

Elligo Health Research, a leading integrated research organization with relationships and access to over 100 community-based healthcare practices and their data, announced it is now able to bring clinical trial opportunities to over 100 million patients.

James Lanthier, CEO of Mindset, commented, “Mindset has developed a range of promising in vitro data from all three of its patent-pending families of next generation psilocybin-inspired drug candidate compounds, including, most recently from its third family.

Since November of 2020, scientist and the medical community have been following three new variants of SARS-CoV-2 with great interest and concern

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that it has issued a shareholder letter and corporate update outlining the Company’s developments and initiatives for 2020 and anticipated milestones for 2021 and beyond.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company executed a Two Million Dollar Convertible Promissory Note Purchase Agreement with Convergent Therapeutics, Inc., securing an early investment in Co

Immunexpress , Inc., today announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric patients with sepsis